Transimmunization and the evolution of extracorporeal photochemotherapy

Transfusion and Apheresis Science

Volumn 26, Issue 3, 2002, Pages 181-190

  Girardi, Michael ^a   Schechner, Jeffrey ^a   Glusac, Earl ^a   Berger, Carole ^a   Edelson, Richard ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Anti tumor; Antigen presenting cell; Cutaneous T cell lymphoma; Dendritic cell; Extracorporeal photochemotherapy; Immunotherapy; Photopheresis; T cell; Transimmunization

Indexed keywords

METHOXSALEN; T LYMPHOCYTE RECEPTOR; TUMOR ANTIGEN;

ANTIGEN PRESENTING CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER IMMUNOTHERAPY; CELL CULTURE; CELL DIFFERENTIATION; CELL FUNCTION; CELL INTERACTION; CELL ISOLATION; CLINICAL PROTOCOL; CLINICAL TRIAL; DENDRITIC CELL; DOWN REGULATION; EVOLUTION; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOMODULATION; IMMUNOTHERAPY; LEUKAPHERESIS; LEUKOCYTE; PHOTOACTIVATION; PHOTOTHERAPY; PUVA; RECEPTOR AFFINITY; REGULATORY MECHANISM; SKIN LYMPHOMA; T CELL LYMPHOMA; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; THEORETICAL STUDY; TRANSIMMUNIZATION; TREATMENT OUTCOME; CYTOLOGY; CYTOTOXIC T LYMPHOCYTE; IMMUNOLOGY; METHODOLOGY; NEOPLASM; REVIEW;

DENDRITIC CELLS; GRAFT VS HOST DISEASE; HUMANS; IMMUNOTHERAPY; NEOPLASMS; PHOTOPHERESIS; T-LYMPHOCYTES, CYTOTOXIC;

EID: 0036257470     PISSN: 14730502     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1473-0502(02)00011-3     Document Type: Article

References (41)

1. Treatment of leukemic cutaneous T-cell lymphoma with extracorporeally-photoactivated 8-methoxypsoralen
2. Photopheresis for the treatment of cutaneous T-cell lymphoma
3. Extracorporeal photochemotherapy alone or with adjuvante therapy in the treatment of cutaneaous T-cell lymphoma: A 9-year retrospective study at a single institution
4. Extracorporeal photochemotherapy for cutaneous T-cell lymphoma: A 9.7-year experience
5. Treatment of erythrodermic cutaneous T-cell lymphoma with extracorporeal photochemotherapy
6. Extracorporeal photopheresis for the treatment of cutaneous T-cell lymphoma
7. Photopheresis therapy for cutaneous T-cell lymphoma
8. Long-term follow-up with cutaneous T-cell lymphoma treated with extracorporeal photochemotherapy
9. Successful use of extracorporeal photochemotherapy in the treatment of severe acute and chronic graft-versus-host disease
10. Extracorporeal photopheresis in the treatment of acute graft-verus-host disease
11. Extracorporeal photopheresis (ECP) in the treatment of chronic graft-versus-host disease (GVHD)
12. Treatment of graft-versus-host disease by extracorporeal photochemotherapy
13. Complete remission of lichen-planus-like graft-versus-host disease (GVHD) with extracorporeal photochemotherapy (CP)
14. Successful treatment of chronic graft-versus-host disease with extracorporeal photopheresis
15. Photopheresis in paediatric patients with drug-resistant chronic graft-versus-host disease
16. Extracorporeal photochemotherapy as single therapy for extensive cutaneous chronic graft-versus-host disease
17. Treatment of systemic sclerosis with extracorporeal photochemotherapy - results of a multicenter trial
18. Photopheresis and systemic sclerosis
19. Extracorporeal photochemotherapy in progressive systemic sclerosis
20. Photopheresis for the prevention of rejection in cardiac transplantation
21. Photopheresis versus corticosteroids in the therapy of heart transplant rejection
22. Photochemotherapy in human heart transplant recipients at high risk for fatal rejection
23. Renal allograft rejection controlled by photopheresis
24. Reversal of acute renal allograft rejection by extracorporeal photopheresis: A case presentation and review of the literature
25. Photopheresis for chronic rejection of lung allografts
26. Extracorporeal photochemotherapy treatment for acute lung rejection episode
27. Dendritic cells: Specialized and regulated antigen-processing machines
28. Dendritic cell vaccines for cancer immunotherapy
29. Induction of human tumor-loaded dendritic cells
30. The immune response to class I-associated tumor-specific cutaneous T-cell lymphoma antigens
31. Tumor-specific peptides in cutaneous T-cell lymphoma: Association with class I major histocompatibility complex and possible derivation from the clonotypic T-cell receptor
32. Linkage of foreign carrier protein to a self-tumor antigen enhances the immunogenicity of a pulsed dendritic cell vaccine
33. The role of human T-cell lymphotropic virus type I tax in the development of cutaneous T-cell lymphoma
34. Specific suppression of lupus-like graft versus host disease using extracorporeal photochemical attenuation of effector lymphocytes
35. Inhibition of antiskin allograft immunity by infusions with syngeneic photoinactivated effector lymphocytes
36. Inhibition of autoimmune disease in a murine model of systemic lupus erythematosus induced by exposure to syngeneic photoinactivated lymphocytes
37. The clonotypic T-cell receptor is a source of tumor-associated antigens in cutaneous T-cell lymphoma
38. Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs
39. Antigen-specific inhibition of effector T-cell function in humans after injection of immature dendritic cells
40. Strong TCR ligation without costimulation causes rapid onset of Fas-dependent apoptosis of T-cells
41. Dendritic cell maturation is required for the cross-tolerization of CD8+ T-cells